Progress of drug-loaded polymeric micelles into clinical studies

Journal of Controlled Release

Volumn 190, Issue , 2014, Pages 465-476

  Cabral, Horacio ^a   Kataoka, Kazunori ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Anticancer drugs; Clinical trials; Gene delivery; Ligand mediated targeting; Polymeric micelles

Indexed keywords

BLOCK COPOLYMERS; BLOOD VESSELS; CONTROLLED DRUG DELIVERY; DRUG INTERACTIONS; GENE TRANSFER; MICELLES; NUCLEIC ACIDS; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; TUMORS;

AMPHIPHILIC BLOCK COPOLYMERS; ANTICANCER DRUG; CLINICAL EVALUATION; CLINICAL TRIAL; ENHANCED PERMEABILITY AND RETENTION EFFECTS; GENE DELIVERY; POLYMERIC MICELLE; THERAPEUTIC EFFICACY;

TARGETED DRUG DELIVERY; POLYMERS;

(TRANS L 1,2 DIAMINOCYCLOHEXANE)PLATINUM; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FIRTECAN; MACROGOL; NANOCARRIER; NC 4016; NC 6004; NC 6300; NK 105; NK 911; NUCLEIC ACID; OXALIPLATIN; PACLITAXEL; POLYMER; UNCLASSIFIED DRUG; COPOLYMER; PLATINUM; SMALL INTERFERING RNA; CAMPTOTHECIN; DELAYED RELEASE FORMULATION; DRUG CARRIER; IRINOTECAN; MICELLE; PLATINUM DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; LYMPHATIC DRAINAGE; MICELLE; PRIORITY JOURNAL; SOLID TUMOR; STEADY STATE; BLOOD VESSEL; DRUG FORMULATION; GENE TARGETING; IMAGING; NEOPLASM; PHASE 1 CLINICAL TRIAL (TOPIC); REVIEW; TISSUES; ANALOGS AND DERIVATIVES; CHEMISTRY; DELAYED RELEASE FORMULATION; NEOPLASMS;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; EPIRUBICIN; HUMANS; MICELLES; NEOPLASMS; PACLITAXEL; PLATINUM COMPOUNDS; POLYMERS;

EID: 84906786049     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.06.042     Document Type: Review

References (114)

1. J. Ferlay, I. Soerjomataram, M. Ervik, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, DM. Parkin, D. Forman, F. Bray, GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 (World Hearth Organization), 2013.
2. R. Duncan The dawning era of polymer therapeutics Nat. Rev. Drug Discov. 2 2003 347 360 (Pubitemid 37361705)
3. M.E. Davis, Z. Chen, and D. Shin Nanoparticle therapeutics: an emerging treatment modality for cancer Nat. Rev. Drug Discov. 7 2008 771 782
4. K. Kataoka, A. Harada, and Y. Nagasaki Block copolymer micelles for drug delivery: design, characterization and biological significance Adv. Drug Deliv. Rev. 47 2001 113 131 (Pubitemid 32209236)
5. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392 (Pubitemid 17221789)
6. N. Nishiyama, and K. Kataoka Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery Pharmacol. Ther. 112 2006 630 648 (Pubitemid 44592613)
7. S.T. Reddy, A.J. van der Vlies, E. Simeoni, V. Angeli, G.J. Randolph, C.P. O'Neil, L.K. Lee, M.A. Swartz, and J.A. Hubbell Exploiting lymphatic transport and complement activation in nanoparticle vaccines Nat. Biotechnol. 25 2007 1159 1164 (Pubitemid 47538111)
8. H. Cabral, Y. Matsumoto, K. Mizuno, Q. Chen, M. Murakami, M. Kimura, Y. Terada, M.R. Kano, K. Miyazono, M. Uesaka, N. Nishiyama, and K. Kataoka Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size Nat. Nanotechnol. 6 2011 815 822
9. M. Murakami, H. Cabral, Y. Matsumoto, S. Wu, M.R. Kano, T. Yamori, N. Nishiyama, and K. Kataoka Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting Sci. Transl. Med. 3 2011 64ra2
10. Y. Matsumura, T. Hamaguchi, T. Ura, K. Muro, Y. Yamada, Y. Shimada, K. Shirao, and T. Okusaka Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin Br. J. Cancer 91 2004 1775 1781 (Pubitemid 39664964)
11. Y. Matsumura, and K. Kataoka Preclinical and clinical studies of anticancer agent-incorporating polymer micelles Cancer Sci. 100 2009 572 579
12. E. Saltiel, and W. McGuire Doxorubicin (adriamycin) cardiomyopathy - a critical review West. J. Med. 139 1983 332 341 (Pubitemid 13007385)
13. R. Duncan, H.C. Cable, J.B. Lloyd, P. Rejmanova, and J. Kopeček Polymers containing enzymatically degradable bonds. 7. Design of oligopeptide side-chains in poly[n-(2-hydroxypropyl)methacrylamide] copolymers to promote efficient degradation by lysosomal-enzymes, Makromol. Chem Macromol. Chem. Phys. 184 1983 1997 2008
14. P.A. Vasey, S.B. Kaye, R. Morrison, C. Twelves, P. Wilson, R. Duncan, A.H. Thomson, L.S. Murray, T.E. Hilditch, T. Murray, S. Burtles, D. Fraier, E. Frigerio, and J. Cassidy Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates Clin. Cancer Res. 5 1999 83 94 (Pubitemid 29045181)
15. S.E. Krown, D.W. Northfelt, D. Osoba, and J.S. Stewart Use of liposomal anthracyclines in Kaposi's sarcoma Semin. Oncol. 31 2004 36 52 (Pubitemid 40023241)
16. P.G. Rose Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer Oncologist 10 2005 205 214 (Pubitemid 40463158)
17. A.T. Perez, G.H. Domenech, C. Frankel, and C.L. Vogel Pegylated liposomal doxorubicin (Doxil®) for metastatic breast cancer: the Cancer Research Network, Inc., experience Cancer Invest. 20 2002 22 29 (Pubitemid 35303440)
18. M. Yokoyama, S. Inoue, K. Kataoka, N. Yui, T. Okano, and Y. Sakurai Molecular design for missile drug: synthesis of adriamycin conjugated with immunoglobulin G using poly(ethylene glycol)-block-poly(aspartic acid) as intermediate carrier Makromol. Chem. 190 1989 2041 2054
19. M. Yokoyama, M. Miyauchi, N. Yamada, T. Okano, Y. Sakurai, I. Shohei, and K. Kataoka Polymeric micelles as novel drug carrier: adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer J. Control. Release 11 1990 269 278 (Pubitemid 20070104)
20. M. Menozzi, L. Valentini, E. Vannini, and F. Arcamone Self-association of doxorubicin and related compounds in aqueous solution J. Pharm. Sci. 73 1984 766 770 (Pubitemid 14122790)
21. S. Fukushima, M. Machida, T. Akutsu, K. Shimizu, S. Tanaka, K. Okamoto, H. Mashiba, M. Yokoyama, T. Okano, Y. Sakurai, and K. Kataoka Roles of adriamycin and adriamycin dimer in antitumor activity of the polymeric micelle carrier system Colloids Surf. B: Biointerfaces 16 1999 227 236 (Pubitemid 29486809)
22. T. Nakanishi, S. Fukushima, K. Okamoto, M. Suzuki, Y. Matsumura, M. Yokoyama, T. Okano, Y. Sakurai, and K. Kataoka Development of the polymer micelle carrier system for doxorubicin J. Control. Release 74 2001 295 302 (Pubitemid 32727635)
23. Y. Zhao, D.Y. Alakhova, J.O. Kim, T.K. Bronich, and A.V. Kabanov A simple way to enhance Doxil® therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer J. Control. Release 168 2013 61 69
24. E.K. Rowinsky, and R.C. Donehower Paclitaxel (Taxol) N. Engl. J. Med. 332 1995 1004 1014
25. Z. Zhang, L. Mei, and S.S. Feng Paclitaxel drug delivery systems Expert Opin. Drug Deliv. 10 2013 325 340
26. M.R. Green, G.M. Manikhas, S. Orlov, B. Afanasyev, A.M. Makhson, P. Bhar, and M.J. Hawkins Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer Ann. Oncol. 17 2006 1263 1268 (Pubitemid 44288216)
27. E. Miele, G.P. Spinelli, E. Miele, F. Tomao, and S. Tomao Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer Int. J. Nanomedicine 4 2009 99 105
28. J.W. Singer Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane J. Control. Release 109 2005 120 126 (Pubitemid 41737258)
29. K.S. Lee, H.C. Chung, S.A. Im, Y.H. Park, C.S. Kim, S.B. Kim, S.Y. Rha, M.Y. Lee, and J. Ro Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer Breast Cancer Res. Treat. 108 2008 241 250 (Pubitemid 351311357)
30. S. Cammas, T. Matsumoto, T. Okano, Y. Sakurai, and K. Kataoka Design of functional polymeric micelles as site-specific drug vehicles based on poly(α-hydroxy ethylene oxide-co-β-benzyl l-aspartate) block copolymers Mater. Sci. Eng. C 4 1997 241 247 (Pubitemid 127406606)
31. K. Kataoka, T. Matsumoto, M. Yokoyama, T. Okano, Y. Sakurai, S. Fukushima, K. Okamoto, and G.S. Kwon Doxorubicin-loaded poly(ethylene glycol)-poly(β-benzyl-l-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance J. Control. Release 64 2000 143 153 (Pubitemid 30035315)
32. T. Hamaguchi, Y. Matsumura, M. Suzuki, K. Shimizu, R. Goda, I. Nakamura, I. Nakatomi, M. Yokoyama, K. Kataoka, and T. Kakizoe NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel Br. J. Cancer 92 2005 1240 1246 (Pubitemid 40604398)
33. T. Hamaguchi, K. Kato, H. Yasui, C. Morizane, M. Ikeda, H. Ueno, K. Muro, Y. Yamada, T. Okusaka, K. Shirao, Y. Shimada, H. Nakahama, and Y. Matsumura A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation Br. J. Cancer 97 2007 170 176 (Pubitemid 47057476)
34. K. Kato, K. Chin, T. Yoshikawa, K. Yamaguchi, Y. Tsuji, T. Esaki, K. Sakai, M. Kimura, T. Hamaguchi, Y. Shimada, Y. Matsumura, and R.I. Ikeda Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer Invest. New Drugs 30 2012 1621 1627
35. Y. Kawato, M. Aonuma, Y. Hirota, H. Kuga, and K. Sato Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11 Cancer Res. 51 1991 4187 4191
36. F. Koizumi, M. Kitagawa, T. Negishi, T. Onda, S. Matsumoto, T. Hamaguchi, and Y. Matsumura Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors Cancer Res. 66 2006 10048 10056 (Pubitemid 44672058)
37. Y. Xiao, and M. Cushman Effect of E-ring modifications in camptothecin on topoisomerase I inhibition: a quantum mechanics treatment J. Org. Chem. 70 2005 9584 9587 (Pubitemid 41611716)
38. J. Kuroda, J. Kuratsu, M. Yasunaga, Y. Koga, Y. Saito, and Y. Matsumura Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma Int. J. Cancer 124 2009 2505 2511
39. M. Sumitomo, F. Koizumi, T. Asano, A. Horiguchi, K. Ito, T. Asano, T. Kakizoe, M. Hayakawa, and Y. Matsumura Novel SN-38-incorporated polymeric micelle, NK012, strongly suppresses renal cancer progression Cancer Res. 68 2008 1631 1635 (Pubitemid 351416546)
40. T.E. Nakajima, K. Yanagihara, M. Takigahira, M. Yasunaga, K. Kato, T. Hamaguchi, Y. Yamada, Y. Shimada, K. Mihara, T. Ochiya, and Y. Matsumura Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan Cancer Res. 68 2008 9318 9322
41. Y. Saito, M. Yasunaga, J. Kuroda, Y. Koga, and Y. Matsumura Enhanced distribution of NK012, a polymeric micelle-encapsulated SN-38, and sustained release of SN-38 within tumors can beat a hypovascular tumor Cancer Sci. 99 2008 1258 1264 (Pubitemid 351676640)
42. Y. Saito, M. Yasunaga, J. Kuroda, Y. Koga, and Y. Matsumura Antitumour activity of NK012, SN-38-incorporating polymeric micelles, in hypovascular orthotopic pancreatic tumour Eur. J. Cancer 46 2010 650 658
43. T.E. Nakajima, M. Yasunaga, Y. Kano, F. Koizumi, K. Kato, T. Hamaguchi, Y. Yamada, K. Shirao, Y. Shimada, and Y. Matsumura Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil Int. J. Cancer 122 2008 2148 2153 (Pubitemid 351441208)
44. T. Nagano, M. Yasunaga, K. Goto, H. Kenmotsu, Y. Koga, J. Kuroda, Y. Nishimura, T. Sugino, Y. Nishiwaki, and Y. Matsumura Antitumor activity of NK012 combined with cisplatin against small cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment Clin. Cancer Res. 15 2009 4348 4355
45. T. Hamaguchi, T. Doi, T. Eguchi-Nakajima, K. Kato, Y. Yamada, Y. Shimada, N. Fuse, A. Ohtsu, S. Matsumoto, M. Takanashi, and Y. Matsumura Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors Clin. Cancer Res. 16 2010 5058 5066
46. S. Fields Jones, H.A. Burris, J.R. Infante, F.A. Greco, D.R. Spigel, S. Kawamura, T. Ishioka, H. Yamazaki, and J.C. Bendell A phase I study of NK012 in combination with 5-fluorouracil with or without leucovorin in patients (pts) with advanced solid tumors J. Clin. Oncol. 30 2012 e13076 (abstr)
47. D. Abigerges, G. Chabot, J. Armand, P. Herait, A. Gouyette, and D. Gandia Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients J. Clin. Oncol. 13 1995 210 221
48. E. Raefsky, D.R. Spigel, J.R. Infante, J.C. Bendell, S.F. Jones, A.J. Lipman, D. Trent, S. Kawamura, F.A. Greco, J.D. Hainsworth, H.A. Burris, Phase II study of NK012 in relapsed small cell lung cancer. J. Clin. Oncol. 2011 ASCO Annual Meeting Abstracts 29 (2011) 7079.
49. C.C. Cain, D.M. Sipe, and R.F. Murphy Regulation of endocytic pH by the Na +, K + -ATPase in living cells Proc. Natl. Acad. Sci. U. S. A. 86 1989 544 548 (Pubitemid 19037778)
50. Y. Bae, S. Fukushima, A. Harada, and K. Kataoka Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change Angew. Chem. Int. Ed. 42 2003 4640 4643 (Pubitemid 37271305)
51. Y. Bae, N. Nishiyama, S. Fukushima, H. Koyama, M. Yasuhiro, and K. Kataoka Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy Bioconjug. Chem. 16 2005 122 130 (Pubitemid 40129685)
52. M. Harada, I. Bobe, H. Saito, N. Shibata, R. Tanaka, T. Hayashi, and Y. Kato Improved anti-tumor activity of stabilized anthracycline polymeric micelle formulation, NC-6300 Cancer Sci. 102 2011 192 199
53. A. Takahashi, Y. Yamamoto, M. Yasunaga, Y. Koga, J. Kuroda, M. Takigahira, M. Harada, H. Saito, T. Hayashi, Y. Kato, T. Kinoshita, N. Ohkohchi, I. Hyodo, and Y. Matsumura NC-6300, an epirubicin-incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin Cancer Sci. 104 2013 920 925
54. E. Wong, and C.M. Giandomenico Current status of platinum-based antitumor drugs Chem. Rev. 99 1999 2451 2466
55. A. Grothey, and R.M. Goldberg A review of oxaliplatin and its clinical use in colorectal cancer Expert. Opin. Pharmacother. 5 2004 2159 2170 (Pubitemid 39406117)
56. H.S. Oberoi, N.V. Nukolova, A.V. Kabanov, and T.K. Bronich Nanocarriers for delivery of platinum anticancer drugs Adv. Drug Deliv. Rev. 65 2013 1667 1685
57. N. Nishiyama, S. Okazaki, H. Cabral, M. Miyamoto, Y. Kato, Y. Sugiyama, K. Nishio, Y. Matsumura, and K. Kataoka Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice Cancer Res. 63 2003 8977 8983 (Pubitemid 38064079)
58. H. Cabral, N. Nishiyama, S. Okazaki, H. Koyama, and K. Kataoka Preparation and biological properties of dichloro (1, 2-diaminocyclohexane) platinum (II)(DACHPt)-loaded polymeric micelles J. Control. Release 101 2005 223 232 (Pubitemid 39600985)
59. M. Yokoyama, T. Okano, Y. Sakurai, S. Suwa, and K. Kataoka Introduction of cisplatin into polymeric micelle J. Control. Release 39 1996 351 356 (Pubitemid 26195838)
60. N. Nishiyama, M. Yokoyama, T. Aoyagi, T. Okano, Y. Sakurai, and K. Kataoka Preparation and characterization of self-assembled polymer-metal complex micelle from cis-dichlorodiammineplatinum(II) and poly(ethylene glycol)-poly(aspartic acid) block copolymer in an aqueous medium Langmuir 15 1999 377 383
61. N. Nishiyama, Y. Kato, Y. Sugiyama, and K. Kataoka Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system Pharm. Res. 18 2001 1035 1041 (Pubitemid 32799952)
62. Y. Mochida, H. Cabral, Y. Miura, F. Albertini, S. Fukushima, K. Osada, N. Nishiyama, and K. Kataoka Bundled assembly of helical nanostructures in polymeric micelles loaded with platinum drugs enhancing therapeutic efficiency against pancreatic tumor ACS Nano 2014 (under revision). Article ASAP, http://dx.doi.org/10.1021/nn500498t Publication Date (Web): June 10, 2014
63. H. Uchino, Y. Matsumura, T. Negishi, F. Koizumi, T. Hayashi, T. Honda, N. Nishiyama, K. Kataoka, S. Naito, and T. Kakizoe Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats Br. J. Cancer 93 2005 678 687 (Pubitemid 41486459)
64. M. Baba, Y. Matsumoto, A. Kashio, H. Cabral, N. Nishiyama, K. Kataoka, and T. Yamasoba Micellization of cisplatin (NC-6004) reduces its ototoxicity in guinea pigs J. Control. Release 157 2012 112 117
65. R. Plummer, R. Wilson, H. Calvert, A. Boddy, M. Griffin, J. Sludden, M. Tilby, M. Eatock, D. Pearson, and C. Ottley A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours Br. J. Cancer 104 2011 593 598
66. W.-C. Su, L.-T. Chen, C.-P. Li, J.-S. Chen, Y.-L. Lin, S.-P. Choo, and Y. Matsumura Phase I/II Study of NC-6004, A Novel Micellar Formulation of Cisplatin, in Combination with Gemcitabine in Patients with Pancreatic Cancer in Asia - Results of Phase I 2012 ESMO (Abstract 863)
67. H. Cabral, N. Nishiyama, and K. Kataoka Optimization of (1,2-diamino-cyclohexane)platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity J. Control. Release 121 2007 146 155 (Pubitemid 47212536)
68. M. Rafi, H. Cabral, M. Kano, P. Mi, C. Iwata, M. Yashiro, K. Hirakawa, K. Miyazono, N. Nishiyama, and K. Kataoka Polymeric micelles incorporating (1, 2-diaminocyclohexane) platinum (II) suppress the growth of orthotopic scirrhous gastric tumors and their lymph node metastasis J. Control. Release 159 2012 189 196
69. S. Deshayes, H. Cabral, T. Ishii, Y. Miura, S. Kobayashi, T. Yamashita, A. Matsumoto, Y. Miyahara, N. Nishiyama, and K. Kataoka Phenylboronic acid-installed polymeric micelles for targeting sialylated epitopes in solid tumors J. Am. Chem. Soc. 135 2013 15501 15507
70. H. Cabral, M. Murakami, H. Hojo, Y. Terada, M.R. Kano, U.-i. Chung, N. Nishiyama, and K. Kataoka Targeted therapy of spontaneous murine pancreatic tumors by polymeric micelles prolongs survival and prevents peritoneal metastasis Proc. Natl. Acad. Sci. U. S. A. 110 2013 11397 11402
71. Y. Yamamoto, I. Hyodo, M. Takigahira, Y. Koga, M. Yasunaga, M. Harada, T. Hayashi, Y. Kato, and Y. Matsumura Effect of combined treatment with the epirubicin-incorporating micelles (NC-6300) and 1,2-diaminocyclohexane platinum (II)-incorporating micelles (NC-4016) on a human gastric cancer model Int. J. Cancer 2013 10.1002/ijc.28651
72. T.M. Allen Ligand-targeted therapeutics in anticancer therapy Nat. Rev. Cancer 2 2002 750 763 (Pubitemid 37328910)
73. V. Torchilin Antibody-modified liposomes for cancer chemotherapy Expert Opin. Drug Deliv. 5 2008 1003 1025
74. W.W. Cheng, and T.M. Allen The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment Expert Opin. Drug Deliv. 7 2010 461 478
75. O.C. Farokhzad, J. Cheng, B.A. Teply, I. Sherifi, S. Jon, P.W. Kantoff, J.P. Richie, and R. Langer Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo Proc. Natl. Acad. Sci. U. S. A. 103 2006 6315 6320
76. M. Oba, Y. Vachutinsky, K. Miyata, M.R. Kano, S. Ikeda, N. Nishiyama, K. Itaka, K. Miyazono, H. Koyama, and K. Kataoka Antiangiogenic gene therapy of solid tumor by systemic injection of polyplex micelles loading plasmid DNA encoding soluble flt-1 Mol. Pharm. 7 2010 501 509
77. Y. Miura, T. Takenaka, K. Toh, S. Wu, H. Nishihara, M.R. Kano, Y. Ino, T. Nomoto, Y. Matsumoto, H. Koyama, H. Cabral, N. Nishiyama, and K. Kataoka Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier ACS Nano 7 2013 8583 8592
78. Y. Bae, W.D. Jang, N. Nishiyama, S. Fukushima, and K. Kataoka Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery Mol. Biosyst. 1 2005 242 250 (Pubitemid 41442434)
79. E. Ruoslahti RGD and other recognition sequences for integrins Annu. Rev. Cell Dev. Biol. 12 1996 697 715 (Pubitemid 26422728)
80. M. Pfaff, K. Tangemann, B. Müller, M. Gurrath, G. Müller, H. Kessler, R. Timpl, and J. Engel Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins J. Biol. Chem. 269 1994 20233 20238 (Pubitemid 24260416)
81. E. Koivunen, B. Wang, and E. Ruoslahti Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins Nat. Biotechnol. 13 1995 265 270
82. D.R. Groothuis The blood-brain and blood-tumor barriers: a review of strategies for increasing, drug delivery J. Neuro Oncol. 2 2000 45 59
83. A. Harada, and K. Kataoka Chain length recognition: core-shell supramolecular assembly from oppositely charged block copolymers Science 283 1999 65 67 (Pubitemid 29044846)
84. K. Kataoka, H. Togawa, A. Harada, K. Yasugi, T. Matsumoto, and S. Katayose Spontaneous formation of polyion complex micelles with narrow distribution from antisense oligonucleotide and cationic block copolymer in physiological saline Macromolecules 29 1996 8556 8557
85. S. Katayose, and K. Kataoka Water-soluble polyion complex associates of DNA and poly(ethylene glycol)-poly(l-lysine) block copolymer Bioconjug. Chem. 8 1997 702 707 (Pubitemid 27416084)
86. Y. Lee, T. Ishii, H. Cabral, H.J. Kim, H.J. Seo, N. Nishiyama, H. Oshima, K. Osada, and K. Kataoka Charge-conversional PIC micelles - an efficient protein delivery nanocarrier into cytoplasm Angew. Chem. Int. Ed. 48 2009 5309 5312
87. K. Itaka, N. Kanayama, N. Nishiyama, W.D. Jang, Y. Yamasaki, K. Nakamura, H. Kawaguchi, and K. Kataoka Supramolecular nanocarrier of siRNA from PEG-based block catiomer carrying diamine side chain with distinctive pKa directed to enhance intracellular gene silencing J. Am. Chem. Soc. 126 2004 13612 13613 (Pubitemid 39407229)
88. S. Uchida, K. Itaka, H. Uchida, K. Hayakawa, T. Ogata, T. Ishii, S. Fukushima, K. Osada, and K. Kataoka In vivo messenger RNA introduction into the central nervous system using polyplex nanomicelle PLoS One 8 2013 e56220
89. H.R. Stapert, N. Nishiyama, D.-L. Jiang, T. Aida, and K. Kataoka Polyion complex micelles encapsulating light-harvesting ionic dendirmer zinc porphyrins Langmuir 16 2000 8182 8188
90. T. Nomoto, Y. Matsumoto, K. Miyata, M. Oba, S. Fukushima, N. Nishiyama, T. Yamasoba, and K. Kataoka In situ quantitative monitoring of polyplexes and polyplex micelles in the blood circulation using intravital real-time confocal laser scanning microscopy J. Control. Release 151 2011 104 109
91. Y. Kakizawa, A. Harada, and K. Kataoka Environment-sensitive stabilization of core-shell structured polyion complex micelle by reversible cross-linking of the core through disulfide bond J. Am. Chem. Soc. 121 1999 11247 11248
92. M. Oba, K. Miyata, K. Osada, R.J. Christie, M. Sanjoh, W. Li, S. Fukushima, T. Ishii, M.R. Kano, N. Nishiyama, H. Koyama, and K. Kataoka Polyplex micelles prepared from ω-cholesteryl PEG-polycation block copolymers for systemic gene delivery Biomaterials 32 2011 652 663
93. K. Miyata, N. Nishiyama, and K. Kataoka Rational design of smart supramolecular assemblies for gene delivery: Chemical challenges in the creation of artificial viruses Chem. Soc. Rev. 41 2012 2562 2574
94. M. Nakanishi, J.-S. Park, W.-D. Jang, M. Oba, and K. Kataoka Study of the quantitative aminolysis reaction of poly(β-benzyl l-aspartate) (PBLA) as a platform polymer for functionality materials React. Funct. Polym. 67 2007 1361 1372 (Pubitemid 47562878)
95. N. Kanayama, S. Fukushima, N. Nishiyama, K. Itaka, W.-D. Jang, K. Miyata, Y. Yamasaki, U.-I. Chung, and K. Kataoka A PEG-based biocompatible block catiomer with high buffering capacity for the construction of polyplex micelles showing efficient gene transfer toward primary cells ChemMedChem 1 2006 439 444
96. H. Uchida, K. Miyata, M. Oba, T. Ishii, T. Suma, K. Itaka, N. Nishiyama, and K. Kataoka Odd-even effect of repeating aminoethylene units in the side chain of N-substituted polyaspartamides on gene transfection profiles J. Am. Chem. Soc. 133 2011 15524 15532
97. K. Itaka, T. Ishii, Y. Hasegawa, and K. Kataoka Biodegradable polyamino acid-based polycations as safe and effective gene carrier minimizing cumulative toxicity Biomaterials 31 2010 3707 3714
98. K. Itaka, S. Ohba, K. Miyata, H. Kawaguchi, K. Nakamura, T. Takato, U.-I. Chung, and K. Kataoka Bone regeneration by regulated in vivo gene transfer using biocompatible polyplex nanomicelles Mol. Ther. 15 2007 1655 1662 (Pubitemid 47289009)
99. R.J. Christie, K. Miyata, Y. Matsumoto, T. Nomoto, D. Menasco, T.-C. Lai, M. Pennisi, K. Osada, S. Fukushima, N. Nishiyama, Y. Yamasaki, and K. Kataoka Effect of polymer structure on micelles formed between siRNA and cationic block copolymer comprising thiols and amidines Biomacromolecules 12 2011 3174 3185
100. R.J. Christie, Y. Matsumoto, K. Miyata, T. Nomoto, S. Fukushima, K. Osada, J. Halnaut, F. Pittella, H.-J. Kim, N. Nishiyama, and K. Kataoka Targeted polymeric micelles for siRNA treatment of experimental cancer by intravenous injection ACS Nano 6 2012 5174 5189
101. H.-J. Kim, T. Ishii, M. Zheng, S. Watanabe, K. Toh, Y. Matsumoto, N. Nishiyama, K. Miyata, and K. Kataoka Multifunctional polyion complex micelle featuring enhanced stability, targetability, and endosome escapability for systemic siRNA delivery to subcutaneous model of lung cancer Drug Deliv. Transl. Res. 4 2014 50 60
102. H.-J. Kim, M. Oba, F. Pittella, T. Nomoto, H. Cabral, Y. Matsumoto, K. Miyata, N. Nishiyama, and K. Kataoka PEG-detachable cationic polyaspartamide derivatives bearing stearoyl moieties for systemic siRNA delivery toward subcutaneous BxPC3 pancreatic tumor J. Drug Target. 20 2012 33 42
103. H. Shimizu, Y. Hori, S. Kaname, K. Yamada, N. Nishiyama, S. Matsumoto, K. Miyata, M. Oba, A. Yamada, K. Kataoka, and T. Fujita siRNA-based therapy ameliorates glomerulonephritis J. Am. Soc. Nephrol. 21 2010 622 633
104. Y. Kakizawa, and K. Kataoka Block copolymer self-assembly into monodispersive nanoparticles with hybrid core of antisense DNA and calcium phosphate Langmuir 18 2002 4539 4543 (Pubitemid 35390132)
105. Y. Kakizawa, S. Furukawa, and K. Kataoka Block copolymer-coated calcium phosphate nanoparticles sensing intracellular environment for oligodeoxynucleotide and siRNA delivery J. Control. Release 97 2004 345 356 (Pubitemid 38759491)
106. Y. Kakizawa, S. Furukawa, A. Ishii, and K. Kataoka Organic-inorganic hybrid-nanocarrier of siRNA constructing through the self-assembly of calcium phosphate and PEG-based block aniomer J. Control. Release 111 2006 368 370
107. M. Zhang, A. Ishii, N. Nishiyama, S. Matsumoto, T. Ishii, Y. Yamasaki, and K. Kataoka PEGylated calcium phosphate nanocomposites as smart environment-sensitive carriers for siRNA delivery Adv. Mater. 21 2009 3520 3525
108. F. Pittella, K. Miyata, Y. Maeda, T. Suma, S. Watanabe, Q. Chen, R.J. Christie, K. Osada, N. Nishiyama, and K. Kataoka Pancreatic cancer therapy by systemic administration of VEGF siRNA contained in calcium phosphate/charge- conversional polymer hybrid nanoparticles J. Control. Release 161 2012 868 874
109. F. Pittella, H. Cabral, Y. Maeda, P. Mi, S. Watanabe, H. Takemoto, H.-J. Kim, N. Nishiyama, K. Miyata, and K. Kataoka Systemic siRNA delivery to a spontaneous pancreatic tumor model in transgenic mice by PEGylated calcium phosphate hybrid micelles J. Control. Release 178 2014 18 24
110. P. Mi, D. Kokuryo, H. Cabral, M. Kumagai, T. Nomoto, I. Aoki, Y. Terada, A. Kishimura, N. Nishiyama, and K. Kataoka Hydrothermally synthesized PEGylated calcium phosphate nanoparticles incorporating Gd-DTPA for contrast enhanced MRI diagnosis of solid tumors J. Control. Release 174 2014 63 71
111. H. Cabral, N. Nishiyama, and K. Kataoka Supramolecular nanodevices: from design validation to theranostic nanomedicine Acc. Chem. Res. 44 2011 999 1008
112. S. Kaida, H. Cabral, M. Kumagai, A. Kishimura, Y. Terada, M. Sekino, I. Aoki, N. Nishiyama, T. Tani, and K. Kataoka Visible drug delivery by supramolecular nanocarriers directing to single-platformed diagnosis and therapy of pancreatic tumor model Cancer Res. 70 2010 7031 7041
113. K. Ikeda, M. Terashima, H. Kawamura, I. Takiyama, K. Koeda, A. Takagane, N. Sato, K. Ishida, T. Iwaya, C. Maesawa, H. Yoshinari, and K. Saito Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration Jpn. J. Clin. Oncol. 28 1998 168 175 (Pubitemid 128525564)
114. P.A. Reece, I. Stafford, R.L. Abbott, C. Anderson, J. Denham, S. Freeman, R.G. Morris, P.G. Gill, and C.L. Olweny Two- versus 24-hour infusion of cisplatin: pharmacokinetic considerations J. Clin. Oncol. 7 1989 270 275 (Pubitemid 19048461)